Form 4: TriSalus Life Sciences Executive Acquires Shares

Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc., acquired 3,990 shares through the company's Employee Stock Purchase Plan.

Summary

• Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc., acquired 3,990 shares of common stock on June 30, 2026.
• The acquisition was made through the company's Employee Stock Purchase Plan.
• The purchase price was $3.87 per share.
• Following this transaction, Ms. Szela beneficially owns 1,077,683 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine transaction under an employee stock purchase plan by an executive, rather than a significant strategic move or financial performance indicator.

Positives

• Executive demonstrates continued investment in the company through the Employee Stock Purchase Plan.
• The acquisition of shares by a key executive can signal confidence in the company's future prospects.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, such as this one from TriSalus Life Sciences, are standard disclosures for insider transactions. These filings provide transparency into the buying and selling activities of company executives and directors, which can be a factor investors consider when evaluating a company's stock.

Stakeholder Impact

• Shareholders: Increased transparency into executive ownership, potentially signaling confidence.
• Employees: The Employee Stock Purchase Plan is utilized, indicating a mechanism for employee investment.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Form 4, Insider Trading, Employee Stock Purchase Plan, Mary T. Szela, Common Stock, Beneficial Ownership